[124] Your views of the Therapeutics Initiative: 2019 Survey
In 2019, the Therapeutics Initiative completed its fifth readership survey to evaluate perceptions of our academic unit and the impact of TI events. We conducted similar surveys in 1996, 2000, 2006, and 2011. In 2019 we invited a 10% random sample of all registered pharmacists in British Columbia (N=588) and a 10% random sample of physicians who receive our letter by mail (N=643) to participate in … [Read more...]
[123] Biosimilars or Biologics: What’s the difference?
According to Greek mythology, the Chimera was a fire-breathing hybrid creature composed of parts of more than one animal, usually depicted as a lion with the head of a goat protruding from its back. Recombinant DNA (rDNA) is DNA created in laboratories, combining genetic material from different organisms appropriately called chimeric DNA. The term “biologics” can refer to a wide range of … [Read more...]
A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia
Dormuth CR, Fisher A, Carney G Pharmacoepidemiology & Drug Safety. 2020 https://doi.org/10.1002/pds.4957 Abstract Purpose: To describe a rapid monitoring plan to assess the impacts of a shift in drug coverage for biosimilar drugs in British Columbia following the introduction of a new policy on 27 May 2019. The Biosimilars Initiative requires users of originator infliximab or … [Read more...]
Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non‐depressed adults: a retrospective cohort study
Carney G, Bassett K, Maclure M, Taylor S, Dormuth CR Addiction. 2020 https://doi.org/10.1111/add.14951 Abstract Background and aims: Pharmacotherapies for smoking cessation are widely prescribed, despite substantial concerns being raised regarding the potential increased risk of cardiovascular (CV) and neuropsychiatric adverse events associated with these treatments. This study aimed to … [Read more...]
Is there Evidence for Starting or Continuing Statins in People over 70?
Dr. Jim Wright, MD, PhD gave this presentation on October 5th, 2019 in Vancouver, BC at the "Bringing Best Evidence to Clinicians" medical education conference marking the 25th anniversary of the UBC Therapeutics Initiative. Dr. Wright is an Emeritus Professor of Pharmacology at UBC and a practicing specialist in Internal Medicine and Clinical Pharmacology. He was one of the founders of the … [Read more...]
Vitamin D: How Much Should I Take?
Dr. Cait O'Sullivan, PharmD, BScPh, BA gave this presentation on October 5th, 2019 in Vancouver, BC at the "Bringing Best Evidence to Clinicians" medical education conference marking the 25th anniversary of the UBC Therapeutics Initiative. Dr. O'Sullivan is a full-time academic detailing pharmacist for the BC Provincial Academic Detailing (PAD) service. Prior to joining the academic detailing … [Read more...]
Herbal cannabis and pharmaceutical cannabinoid treatment following motor vehicle accidents: A state of the science review
This is a state of the science review produced at the request of the Insurance Corporation of British Columbia (ICBC) to assist in developing funding policy for insurance claims involving the use of herbal cannabis and pharmaceutical cannabinoids for post injury medical management. Section 1 of the report provides an overall framework for funding policy for ICBC and a summary of clinical trial … [Read more...]
Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study
Daneman N, Chateau D, Dahl M, Zhang J, Fisher A, Sketris IS, Quail J, Marra F, Ernst P, Bugden S, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators Clinical Microbiology and Infection. 2019 https://doi.org/10.1016/j.cmi.2019.10.016 Abstract Objectives: The United States Food & Drug Administration released an advisory in 2016 that fluoroquinolones be … [Read more...]
Comparative Effectiveness Of Fluoroquinolone Antibiotic Use In Uncomplicated Acute Exacerbations Of COPD: A Multi-Cohort Study
Ernst P, Dahl M, Chateau D, Daneman N, Quail J, Sketris IS, Fisher A,Zhang J, Bugden S, on behalf of the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators International Journal of Chronic Obstructive Pulmonary Disease. 2019:14 2939–2946. https://doi.org/10.2147/COPD.S226324 Abstract Purpose: Fluoroquinolone antibiotics are associated with rare, but severe … [Read more...]
Comparison of cholinesterase inhibitor safety in real-world practice
Carney G, Bassett K, Wright JM, Maclure M, McGuire N, Dormuth CR Alzheimer's & Dementia: Translational Research & Clinical Interventions. Volume 5, 2019, Pages 732-739. https://doi.org/10.1016/j.trci.2019.09.011 Highlights Galantamine was associated with fewer adverse events than donepezil or rivastigmine. Galantamine users experienced longer independent living. The … [Read more...]
- 1
- 2
- 3
- …
- 25
- Next Page »
